PLX5622 manufacturers
- PLX5622
-
- $97.00 / 5mg
-
2024-11-18
- CAS:1303420-67-8
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- PLX5622
-
- $150.00 / 1KG
-
2024-08-27
- CAS:1303420-67-8
- Min. Order: 1KG
- Purity: 0.99
- Supply Ability: 20 tons
- PLX5622
-
- $2900.00 / 10g
-
2023-05-23
- CAS:1303420-67-8
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 5000
|
| | PLX5622 Basic information |
| Product Name: | PLX5622 | | Synonyms: | PLX5622;PLX 5622;PLX-5622;3-Pyridinemethanamine, 5-fluoro-N-[6-fluoro-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-2-methoxy-;5-Fluoro-N-[6-fluoro-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-2-methoxy-3-pyridinemethanamine;PLX5622 USP/EP/BP;6-FLUORO-N-((5-FLUORO-2-METHOXYPYRIDIN-3-YL)METHYL)-5-((5-METHYL-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE;PLX5622,PLX 5622,Inhibitor,CSF-1 receptor,microglial,CSF1R,orally,pathology,inhibit,c-Fms,penetrant,preceding,brain,colony stimulating factor 1 receptor,CSF-1R,elimination;6-Fluoro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-7-azaindole-3-yl)methyl]pyridin-2-amine | | CAS: | 1303420-67-8 | | MF: | C21H19F2N5O | | MW: | 395.41 | | EINECS: | | | Product Categories: | API | | Mol File: | 1303420-67-8.mol |  |
| | PLX5622 Chemical Properties |
| density | 1.364±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (>25 mg/ml) | | form | solid | | pka | 13?+-.0.40(Predicted) | | color | Pale yellow | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| | PLX5622 Usage And Synthesis |
| Description | PLX5622 (1303420-67-8) is a highly selective (>20 fold over KIT and FLT3, >60 fold over 200 other kinases) and brain-penetrant inhibitor of colony-stimulating factor 1 receptor (CSF1R; IC50 = 16 nM).1 It prevented plaque formation in 5xFAD1 and 3xTg2 mouse models of Alzheimer’s disease via elimination of microglia in a CSF1R-dependent manner.? PLX5622 showed efficacy in a mouse neuropathic pain model via reduction of CD86+ macrophages resulting in reduced expression of pro-inflammatory cytokines.3 It also was able to ameliorate peripheral neuropathy in aging mice.4 PLX5622 displayed neuroprotective effects during the chronic phase of a traumatic brain injury mouse model.5? PLX5622 has also been shown to affect myeloid and lymphoid compartments, indicating that its affects are not limited to microglia and include peripheral immune cells.6 | | References | Spangenberg et al. (2019) Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model; Nat. Commun.?10 3758
Dagher et al. (2015) Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice; J.? Neuroinflammation 12 139
Lee et al. (2018) Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain; Mol.? Pain?14 1
Yaun et al. (2018) Macrophage Depletion Ameliorates Peripheral Neuropathy in Aging Mice.; J.? Neurosci.?38 4610
Henry et al. (2020) Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits.; J.? Neurosci.?40 2960
Lei et al. (2020) CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages.; Proc. ?Natl. Acad. Sci USA?117 23336 |
| | PLX5622 Preparation Products And Raw materials |
|